Cantor Fitzgerald Forecasts MNMD FY2025 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Mind Medicine (MindMed) in a report released on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings of ($1.39) per share for the year. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

A number of other research analysts have also recently commented on MNMD. Chardan Capital reiterated a “buy” rating and issued a $20.00 price objective on shares of Mind Medicine (MindMed) in a report on Friday, May 9th. Evercore ISI started coverage on shares of Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They set an “outperform” rating and a $23.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Finally, Robert W. Baird cut their price target on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, March 7th. Ten analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mind Medicine (MindMed) currently has a consensus rating of “Buy” and a consensus target price of $25.11.

Mind Medicine (MindMed) Price Performance

Shares of MNMD stock opened at $6.54 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00. The company has a market capitalization of $492.91 million, a PE ratio of -2.89 and a beta of 2.52. The firm’s 50-day moving average is $6.11 and its two-hundred day moving average is $6.95. Mind Medicine has a 12 month low of $4.70 and a 12 month high of $10.44.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.01.

Institutional Investors Weigh In On Mind Medicine (MindMed)

Institutional investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in shares of Mind Medicine (MindMed) by 203.6% in the 3rd quarter. Barclays PLC now owns 136,098 shares of the company’s stock valued at $775,000 after buying an additional 91,271 shares during the period. JPMorgan Chase & Co. lifted its holdings in Mind Medicine (MindMed) by 8.2% in the third quarter. JPMorgan Chase & Co. now owns 36,995 shares of the company’s stock valued at $211,000 after acquiring an additional 2,797 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Mind Medicine (MindMed) by 21.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,430 shares of the company’s stock worth $87,000 after purchasing an additional 2,230 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Mind Medicine (MindMed) by 48.8% during the 4th quarter. SG Americas Securities LLC now owns 24,406 shares of the company’s stock worth $170,000 after purchasing an additional 8,004 shares during the period. Finally, Foundations Investment Advisors LLC purchased a new position in shares of Mind Medicine (MindMed) in the 4th quarter valued at about $91,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Insider Buying and Selling at Mind Medicine (MindMed)

In other Mind Medicine (MindMed) news, insider Daniel Karlin sold 6,836 shares of the business’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $46,074.64. Following the transaction, the insider now directly owns 446,177 shares of the company’s stock, valued at approximately $3,007,232.98. The trade was a 1.51% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert Barrow sold 21,208 shares of the firm’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $142,941.92. Following the completion of the sale, the chief executive officer now owns 856,556 shares of the company’s stock, valued at $5,773,187.44. This trade represents a 2.42% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,391 shares of company stock worth $204,835. 2.45% of the stock is owned by company insiders.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.